← Human Trials & Peer-Reviewed Studies
Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial
Plain-language guide to PMID 22237064 (2012): randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide) in 737 adults, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 22237064
- Journal
- The American journal of clinical nutrition
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Qi Q et al. (5 authors)
- DOI
- 10.3945/ajcn.111.025270
What This Study Did, in Plain Language
What Was Tested
Researchers studied GIP (Gastric Inhibitory Polypeptide) in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
Glucose-dependent insulinotropic polypeptide [also known as gastric inhibitory polypeptide (GIP)] and its receptor (GIPR) may link overnutrition to obesity, insulin resistance, and type 2 diabetes.
Who Took Part
The study group was 737 adults.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
The researchers genotyped the GIPR rs2287019 in 737 overweight adults who were randomly assigned to 1 of 4 weight-loss diets that varied in macronutrient contents for 2 y.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.
The researchers assessed the percentage changes in body weight, fasting glucose, and insulin resistance (HOMA-IR) across genotypes by the low-fat and high-fat diets.
What Was Measured
The subject headings attached to it are Alleles, Blood Glucose, Diet, Fat-Restricted, Diet, Reducing, Dietary Fats, Fasting and Genotype.
What This Means in Plain Language
The paper is a randomized study of GIP (Gastric Inhibitory Polypeptide) in 737 adults in people with insulin resistance, prediabetes & type 2 diabetes.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2012 (The American journal of clinical nutrition), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
- Insulin resistance, prediabetes & type 2 diabetes research
- GIP (Gastric Inhibitory Polypeptide) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.